28-05-2008 дата публикации
Номер: CN0101185628A
Принадлежит:
An irinotecan sustained release implant includes effective dose of anticancer irinotecan, sustained release excipients and a certain quantity of sustained release moderator. Solid tumors include pancreatic cancer, lung cancer, liver cancer, breast cancer, cerebroma, ovarian cancer, prostatic carcinoma, esophageal carcinoma, lymphadenoma, osteosarcoma and colorectal cancer. Sustained release excipients are mainly one or combination of copolymer of glycolic acid and hydroxyacetic acid, polifeprosan, poly(L-lactide-co-ethyl phosphate), and poly (L-lactide-co-phosphoric acid propyl); in the process of decompression, irinotecanpto can be slowly and steadily released to local tumor, thus maintaining effective drug concentration of local tumor as well as significantly reducing overall toxic reaction. Being placed in local tumor, the sustained release implant not only reduces overall toxic reaction of irinotecan, but also selectively improves drug concentration in local tumor, enhancing the therapeutic ...
Подробнее